Tuesday, April 5, 2022

Denmark drops Johnson and Johnson’s Covid-19 vaccine rollout over side effects – ET HealthWorld

Denmark on Monday dropped Johnson and Johnson’s Covid-19 vaccine rollout due to concerns over jab’s side effects.

“The Danish Health Authority has concluded that the benefits of using the Covid-19 vaccine from Johnson & Johnson do not outweigh the risk of causing the possible adverse effect, Vaccine-induced Thrombotic Thrombocytopenia (VITT), in those who receive the vaccine. Therefore, the Danish Health Authority will continue the Danish mass vaccination programme against Covid-19 without the Covid-19 vaccine from Johnson & Johnson,” read a statement by Denmark’s health authority, reported Euronews.

Earlier, Denmark had also dropped AstraZeneca’s vaccine over concerns of “rare” but “serious” side effects. The decision was not an easy one to make.

“Taking the present situation in Denmark into account, what we are currently losing in our effort to prevent severe illness from Covid-19 cannot outweigh the risk of causing possible side effects in the form of severe blood clots in those we vaccinate,” the statement said.

The health authority added that the decision “will significantly affect” the vaccination rollout for people aged between 20 and 39, which will be delayed by up to four weeks.

“The remaining target groups will experience a delay of about one week, as we will be getting large amounts of other vaccines,” read the statement.

“This decision will, of course, have consequences for those who now have their vaccination postponed. For example, they will have to wait longer for the corona passport that so many of us are looking forward to getting. Age is the main risk factor for severe illness from Covid-19, and these are younger citizens who are not at risk of becoming seriously ill,” it said.

As of May 1, more than 1.3 million of the country’s 5.8 million population had received at least one dose of the vaccine, according to Our World in Data.

The Johnson & Johnson vaccine, known as Janssen, in March became the fourth jab to be approved for use across the European Union by the European Medicines Agency (EMA) after Pfizer/BioNTech, AstraZeneca/Oxford University and Moderna, reported Euronews.

But the American pharmaceutical delayed its deliveries to the 27-member bloc after reports of serious blood clots emerged in the US where more than 6.8 million people have received at least one shot.

The EMA launched a review last month but said it remained of the opinion that “the benefits of the vaccine in preventing Covid-19 outweigh the risks of side effects”, reported Euronews.

Source link

Latest Articles

Widely used chemical linked to 1,00,000 US deaths per year: Study

NEW YORK: Daily exposure to phthalates, a group of chemicals used in everything from plastic containers to makeup, may lead to approximately 100,000 deaths...

Foods to Reduce Inflammation and Strengthen the Immune System

Did you know that you can greatly reduce inflammation and boost your immune system by simply incorporating more anti-inflammatory foods and beverages into your...

Personal Selling

INTRODUCTION Early sellers and traders were not held in high esteem. The Roman word for salesman meant ‘Cheater’ and...

Building Muscle on a Vegan Diet

There are a lot of  misconceptions surrounding veganism. The notion that those who practice it are lacking in protein and therefore muscles is the...

Electrodes in brain new hope for severe cases of epilepsy

Neurosurgeons at All India Institute of Medical Sciences have devised a new technique for operating on children suffering from a severe form of epilepsy...